Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
| Revenue (Most Recent Fiscal Year) | $2.36B |
| Net Income (Most Recent Fiscal Year) | $341.30M |
| PE Ratio (Current Year Earnings Estimate) | 32.64 |
| PE Ratio (Trailing 12 Months) | 41.92 |
| PEG Ratio (Long Term Growth Estimate) | 1.27 |
| Price to Sales Ratio (Trailing 12 Months) | 5.07 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.82 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 36.59 |
| Pre-Tax Margin (Trailing 12 Months) | 19.32% |
| Net Margin (Trailing 12 Months) | 12.68% |
| Return on Equity (Trailing 12 Months) | 11.81% |
| Return on Assets (Trailing 12 Months) | 8.59% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.13 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.02 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.70 |
| Book Value per Share (Most Recent Fiscal Quarter) | $25.62 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.08 |
| Earnings per Share (Most Recent Fiscal Year) | $3.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.95 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 98.97M |
| Free Float | 94.22M |
| Market Capitalization | $12.24B |
| Average Volume (Last 20 Days) | 1.51M |
| Beta (Past 60 Months) | 0.26 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.59% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |